0001628280-24-042115.txt : 20241003 0001628280-24-042115.hdr.sgml : 20241003 20241003160733 ACCESSION NUMBER: 0001628280-24-042115 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240903 FILED AS OF DATE: 20241003 DATE AS OF CHANGE: 20241003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KAZIMI A J CENTRAL INDEX KEY: 0001075050 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33637 FILM NUMBER: 241351495 MAIL ADDRESS: STREET 1: 1207 17TH AVENUE SUITE 103 CITY: NASHVILLE STATE: TN ZIP: 37212 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001087294 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE, STATE: TN ZIP: 37203 BUSINESS PHONE: 615-255-0068 MAIL ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 wk-form4_1727986047.xml FORM 4 X0508 4 2024-09-03 0 0001087294 CUMBERLAND PHARMACEUTICALS INC CPIX 0001075050 KAZIMI A J 1600 WEST END AVE. SUITE 1300 NASHVILLE TN 37203 1 1 1 0 Chairman and CEO 1 Common Stock 2024-09-03 5 L 0 E 50 1.38 A 5697753 D Common Stock 2024-09-04 5 L 0 E 47 1.35 A 5697800 D Common Stock 2024-09-05 5 L 0 E 46 1.28 A 5697846 D Common Stock 2024-09-06 5 L 0 E 10 1.30 A 5697856 D Common Stock 2024-09-09 5 L 0 E 50 1.33 A 5697906 D Common Stock 2024-09-10 5 L 0 E 31 1.30 A 5697937 D Common Stock 2024-09-11 5 L 0 E 48 1.35 A 5697985 D Common Stock 2024-09-12 5 L 0 E 50 1.38 A 5698035 D Common Stock 2024-09-13 5 L 0 E 50 1.30 A 5698085 D Common Stock 2024-09-16 5 L 0 E 50 1.30 A 5698135 D Common Stock 2024-09-17 5 L 0 E 50 1.30 A 5698185 D Common Stock 2024-09-18 5 L 0 E 50 1.30 A 5698235 D Common Stock 2024-09-19 5 L 0 E 50 1.29 A 5698285 D Common Stock 2024-09-20 5 L 0 E 50 1.30 A 5698335 D Common Stock 2024-09-23 5 L 0 E 50 1.25 A 5698385 D Common Stock 2024-09-24 5 L 0 E 15 1.22 A 5698400 D Common Stock 2024-09-25 5 L 0 E 39 1.29 A 5698439 D Common Stock 2024-09-26 5 L 0 E 50 1.24 A 5698489 D Common Stock 2024-09-27 5 L 0 E 44 1.24 A 5698533 D Common Stock 2024-09-30 5 L 0 E 62 1.36 A 5698595 D The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2024. A.J. Kazimi by /s/ John Hamm as attorney-in-fact 2024-10-03